COMP <GO>
PNTG vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
The Pennant Group Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PNTG 2
— MRK 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRK
LAST: $42.48 (+0.76%) • MKT CAP: $1.48B
balance-sheet
2.81
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PNTG VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PNTG | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.00% | 20.70% | -9.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.9x | 15.3x | +8.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.44% | 3.42% | -0.98 | MRK | /fcf-yield <GO> |
| Operating Margin | 5.50% | 34.30% | -28.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 3.10% | 28.10% | -25.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 36.30% | 1.30% | +35.00 | PNTG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.81 | 5.19 | -2.38 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 51.7 | +5.90 | PNTG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.2x | 18.4x | +23.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.48B | $361.02B | -$359.54B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PNTG REV | MRK REV | PNTG GROSS % | MRK GROSS % | PNTG FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $947.7M | $65.01B | — | 74.8% | $36.3M | $12.36B |
| FY 2024 | $695.2M | $64.17B | — | 76.3% | $30.3M | $18.10B |
| FY 2023 | $544.9M | $60.12B | — | — | $33.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PNTG // BETA —
MRK // BETA 0.92